Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,251

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,251 results for “ovarian cancer”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov36/100

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

ClinicalTrials.gov study NCT01309230. IPD Sharing: NO. Countries: 1. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

ClinicalTrials.gov study NCT01003938. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

ClinicalTrials.gov study NCT03326193. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

ClinicalTrials.gov study NCT04608409. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

ClinicalTrials.gov study NCT01617629. IPD Sharing: Not stated. Countries: 2. Publications: 8.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

ClinicalTrials.gov study NCT03642132. IPD Sharing: YES. Countries: 10. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

ClinicalTrials.gov study NCT01227928. IPD Sharing: Not stated. Countries: 4. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

ClinicalTrials.gov study NCT00976911. IPD Sharing: Not stated. Countries: 14. Publications: 7.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

ClinicalTrials.gov study NCT00617773. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

ClinicalTrials.gov study NCT03225170. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

ClinicalTrials.gov study NCT00322881. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopi

ClinicalTrials.gov study NCT02631876. IPD Sharing: Not stated. Countries: 13. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

ClinicalTrials.gov study NCT02489903. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

ClinicalTrials.gov study NCT01681368. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
dryad36/100

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

Open the record for dataset details and reuse information.

publicJul 2023View details →
zenodo32/100

MiRoR10 - P1 - Dataset A systematic review finds that spin or interpretation bias is abundant in evaluations of ovarian cancer biomarkers

<p>This dataset is related to &quot;A systematic review finds that spin or interpretation bias is abundant in evaluations of ovarian cancer biomarkers&quot; (Mona Ghannad, Maria Olsen,&nbsp;Isabelle Boutron, Patrick M. Bossuyt)</p>

opencc-by-4.0Jul 2019View details →
zenodo32/100

TCGA breast and ovarian cancer PrediXcan models

<p>TCGA breast and ovarian cancer PrediXcan models</p>

opencc-by-4.0May 2020View details →
dryad32/100

MiRNA-103/107 in primary high-grade serous ovarian cancer and its clinical significance

<p>High levels of miRNA-103/107 are associated with poor outcome in case of breast cancer patients. MiRNA-103/107- DICER axis may be one of the key regulators of cancer aggressiveness. MiRNA-103/107 expression levels have never been related to patients' survival in epithelial ovarian cancer. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues. Expression levels of both miRNAs were related to the clinicopathological features and survival. We also evaluated expression levels of miRNA-103/107 and DICER in selected ovarian cancer cell lines (A2780, A2780cis, SK-OV-3, OVCAR3).</p> <p>We assessed relative expression of miRNA-103/107  (quantitative reverse transcription polymerase chain reaction) in fifty archival formalin-fixed paraffin embedded tissue samples of primary high grade serous ovarian cancer . Then, miRNA-103/107 and DICER expression levels were evaluated in selected ovarian cancer cells lines. Additionally,  DICER, N-/E-cadherin protein levels were assessed with the use of western blot.</p> <p>We identified miRNA-107 up-regulation in ovarian cancer in comparison to healthy tissues (p=0.0005). In case of miRNA-103, we did not observe statistically significant differences between cancerous and healthy tissues (p=0.07).  We did not find any correlations between miRNA-103/107 expression levels and clinicopathological features. Kaplan-Meier survival (disease free and overall survival) analysis revealed that both miRNAs cannot be considered as prognostic factors. SK-OV-3 cancer cell lines was characterised by high expression of miRNA-103/107, relatively low expression of DICER (western-blot) and relatively high N-cadherin levels in comparison to other ovarian cancer cell lines.</p> <p>Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study.</p>

opencc-zeroJul 2020View details →
zenodo32/100

Whole Cancer Cell Vaccine Protects Ovarian Functions in Tumor-bearing Mice through Downregulating CXCL10

<p><span>Young female patients with cancer are likely to become sub-fertile or infertile even if they ultimately overcome cancer through various therapies. Cancer immunotherapy has recently emerged as a promising novel therapy against cancers with high malignancy and lethality, but it is unclear whether cancer immunotherapy affects female fertility. This study employed MCA205 cell-allotransplanted B6 mice as a model to investigate whether two popular immunotherapies&mdash;PD-1 monoclonal antibody (PD-1) therapy and whole cancer cell vaccine (WCV) therapy&mdash;affect ovarian function. MCA205 allotransplanted (M) mice exhibited decreased follicle numbers at each stage, decreased proliferation, increased apoptosis, and a decreased oocyte maturation rate. WCV treatment significantly reversed these abnormalities, whereas PD-1 did not. RNA sequencing of the ovaries revealed that multiple differentially expressed genes (DEGs) were involved in inflammation pathways. Furthermore, cytokine microarray characterized CXCL10 with both biggest increment in M group and best rescue in WCV group. Next, CXCL10 antibody Immunoprecipitation in ovarian lysate and LC-MS baited the only receptor IL18R1. Furthermore, we found that CXCL10 impaired ovarian function through three pathways: inducing ovarian fibrosis through CXCL10&rarr;IL18R1&rarr;p-JNK&rarr;COL1A1, promoting primordial follicle overactivation through CXCL10&rarr;IL18R1&rarr;p-AKT, and increasing ovarian inflammation through CXCL10&rarr;IL18R1&rarr;p-P65. Finally, we rescued the decreased ovarian function in the M group by blocking the CXCL10&rarr;IL18R1 pathway with CXCL10 antibody or a CXCL10&ndash;IL18R1 interface peptide, CIBB. This study provides mechanical evidence and translational strategies for WCVs to achieve the dual functions of suppressing tumor progression while protecting ovarian function.</span></p> <p><strong><span>Supplementary dataset 1</span></strong></p> <p><span>Related to Fig. 3A and 3B. This file includes two sheets. &ldquo;All_samples-fpkm&rdquo; includes FPKM values of all identified genes in ovaries from CTR, M, VM, and PM group (three repeats per group); &ldquo;heat map&rdquo; includes all average log2 values (from three repeats per group) of 435 DEGs (</span><span>differentially expressed genes</span><span>) </span><span>at the threshold of |log2(M/CTR)| &ge; 1.</span></p> <p><strong><span>Supplementary dataset 2</span></strong></p> <p><span>Related to Fig. 3C. This file includes 33 sheets. &ldquo;summary&rdquo; includes all conc. values (pg/ml) of 31 plasma DECs (</span><span>differentially expressed cytokines</span><span>); &ldquo;Curves&rdquo; includes standard curves for all 31 cytokines; each of the other 31 sheets include the detailed assays for each plasma cytokine for CTR, M, VM, and PM group (five repeats per group).</span></p> <p><strong><span>Supplementary dataset 3</span></strong></p> <p><span>Related to Fig. 4A. This file includes two sheets. &ldquo;peptides&rdquo; includes all related values of all identified peptides; &ldquo;Protein Groups&rdquo; includes the related info. Of all proteins corresponding to the identified peptides</span></p>

opencc-by-4.0Mar 2024View details →
zenodo32/100

Data for multi-dimensional characterization of cellular states in ovarian cancer reveals clinically relevant immunological subtypes and therapeutic vulnerabilities

<p>The data for figures</p>

opencc-by-4.0Mar 2024View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record